Press

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Jun 5 • 5 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188…

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Jun 5 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is now actively participating on the Webull Corporate Communications Service (CCS) Platform. The Silo Pharma portal on Webull offers an additional channel for direct investor communication and audience engagement, including Q&A. “We are excited…

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Jun 5 • 1 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023, at 1:00 p.m. ET / 10:00 a.m. PT. The discussion will focus on the Company’s strategic initiatives underway…

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Jun 1 • 6 min read

Reunion Neuroscience Inc. (NASDAQ: REUN / TSX: REUN), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has entered into a definitive arrangement agreement dated May 31, 2023 (the “Arrangement Agreement“) with MPM BioImpact (“MPM”), a world-leading biotechnology investment firm, whereby affiliates of MPM…

atai Life Sciences to Participate in Upcoming June Investor Conferences

Jun 1 • 2 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences. Details of the company’s participation are as follows: Jefferies 2023 Healthcare Conference Format: Corporate Presentation Date and Time: Friday, June 9th, 9:00 a.m. ET Location: New York, NY H.C. Wainwright 4th Annual…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435